Orion Oyj (OTCMKTS:ORINY) Sees Significant Growth in Short Interest

Orion Oyj (OTCMKTS:ORINY) was the target of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 600 shares, a growth of 20.0% from the February 13th total of 500 shares. Based on an average daily trading volume, of 700 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.0% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Nordea Equity Research lowered shares of Orion Oyj to a “hold” rating in a research note on Tuesday, February 4th.

Orion Oyj Stock Performance

Shares of ORINY traded up $0.81 during midday trading on Wednesday, reaching $30.57. 306 shares of the stock were exchanged, compared to its average volume of 3,307. Orion Oyj has a twelve month low of $17.50 and a twelve month high of $30.57. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.42 and a quick ratio of 1.41. The company has a market capitalization of $8.63 billion, a price-to-earnings ratio of 24.26 and a beta of 0.25. The business’s 50-day moving average price is $26.95 and its 200 day moving average price is $25.50.

Orion Oyj (OTCMKTS:ORINY) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.28 EPS for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. The company had revenue of $463.41 million for the quarter. On average, sell-side analysts expect that Orion Oyj will post 1.18 EPS for the current fiscal year.

Orion Oyj Increases Dividend

The firm also recently declared a dividend, which will be paid on Tuesday, April 29th. Investors of record on Monday, April 7th will be given a $0.4478 dividend. This is an increase from Orion Oyj’s previous dividend of $0.24. The ex-dividend date is Monday, April 7th. Orion Oyj’s dividend payout ratio is 26.40%.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.